 The FDAs Office of New Drugs OND, Center for Drug Evaluation and Research CDER, has provided an interim response to Ardelyx Incs NASDAQ: ARDX second level of appeal of the Complete Response Letter CRL for Xphozah. Ardelyx is seeking approval for Xphozah. 